Maya Xania Bjoern1, Sarah Nielsen2, Sharaf Karim Perdawood3. 1. Department of Surgery, Slagelse Hospital, Ingemannsvej 30, 4200, Slagelse, Denmark. mxbjoern@gmail.com. 2. Department of Surgery, Zealand University Hospital, Køge, Denmark. 3. Department of Surgery, Slagelse Hospital, Ingemannsvej 30, 4200, Slagelse, Denmark.
Abstract
BACKGROUND: The aim in rectal cancer surgery is to cure with minimal impact on the quality of life. Transanal total mesorectal excision (TaTME) seems to be a safe and feasible alternative to laparoscopic TME (LaTME). However, limited data are available on the functional outcomes after TaTME. We aimed to study the quality of life (QoL), through questionnaires, comparing different functional outcomes after TaTME and LaTME. METHODS: Consecutive patients who underwent TME between 2010 and 2017 at Slagelse Hospital, Denmark, were included based on certain criteria. Patients were divided according to the surgical technique (TaTME vs LaTME). The study was based on telephone interviews using the questionnaires: EORTC-QLQ C30, EORTC-QLQ C29, Low Anterior Resection Syndrome (LARS) score, and International Prostate Symptom Score (IPSS) for male patients. Patients in this study had a follow-up time of at least 8 months. RESULTS: Overall, global health status was similar between the groups (p = 0.625). Anorectal symptoms were significantly in disfavor of TaTME including buttock pain (p = 0.011), diarrhea (p = 0.009), clustering of stools (p = 0.017), and urgency (p = 0.032), yet total LARS score was comparable (p = 0.054). We found comparable sexual results and an overall higher satisfaction with urinary status in TaTME group (p = 0.010), yet no difference in IPSS symptoms (p = 0.236). CONCLUSIONS: Anorectal dysfunction may occur after total mesorectal excision (TME) regardless of surgical technique, frequently more in after TaTME. The LARS symptoms and the overall quality of life status were however comparable. TaTME had a positive impact on the reported QoL, related to urinary symptoms.
BACKGROUND: The aim in rectal cancer surgery is to cure with minimal impact on the quality of life. Transanal total mesorectal excision (TaTME) seems to be a safe and feasible alternative to laparoscopic TME (LaTME). However, limited data are available on the functional outcomes after TaTME. We aimed to study the quality of life (QoL), through questionnaires, comparing different functional outcomes after TaTME and LaTME. METHODS: Consecutive patients who underwent TME between 2010 and 2017 at Slagelse Hospital, Denmark, were included based on certain criteria. Patients were divided according to the surgical technique (TaTME vs LaTME). The study was based on telephone interviews using the questionnaires: EORTC-QLQ C30, EORTC-QLQ C29, Low Anterior Resection Syndrome (LARS) score, and International Prostate Symptom Score (IPSS) for male patients. Patients in this study had a follow-up time of at least 8 months. RESULTS: Overall, global health status was similar between the groups (p = 0.625). Anorectal symptoms were significantly in disfavor of TaTME including buttock pain (p = 0.011), diarrhea (p = 0.009), clustering of stools (p = 0.017), and urgency (p = 0.032), yet total LARS score was comparable (p = 0.054). We found comparable sexual results and an overall higher satisfaction with urinary status in TaTME group (p = 0.010), yet no difference in IPSS symptoms (p = 0.236). CONCLUSIONS:Anorectal dysfunction may occur after total mesorectal excision (TME) regardless of surgical technique, frequently more in after TaTME. The LARS symptoms and the overall quality of life status were however comparable. TaTME had a positive impact on the reported QoL, related to urinary symptoms.
Authors: Victor W Fazio; Massarat Zutshi; Feza H Remzi; Yann Parc; Reinhard Ruppert; Alois Fürst; James Celebrezze; Susan Galanduik; Guy Orangio; Neil Hyman; Leslie Bokey; Emmanuel Tiret; Boris Kirchdorfer; David Medich; Marcus Tietze; Tracy Hull; Jeff Hammel Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: R N Whistance; T Conroy; W Chie; A Costantini; O Sezer; M Koller; C D Johnson; S A Pilkington; J Arraras; E Ben-Josef; A M Pullyblank; P Fayers; J M Blazeby Journal: Eur J Cancer Date: 2009-09-16 Impact factor: 9.162
Authors: J Andersson; E Angenete; M Gellerstedt; U Angerås; P Jess; J Rosenberg; A Fürst; J Bonjer; E Haglind Journal: Br J Surg Date: 2013-06 Impact factor: 6.939
Authors: Phil Quirke; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Jean Couture; Chris O'Callaghan; Arthur Sun Myint; Eric Bessell; Lindsay C Thompson; Mahesh Parmar; Richard J Stephens; David Sebag-Montefiore Journal: Lancet Date: 2009-03-07 Impact factor: 79.321
Authors: J A G van der Heijden; T Koëter; L J H Smits; C Sietses; J B Tuynman; A J G Maaskant-Braat; B R Klarenbeek; J H W de Wilt Journal: Br J Surg Date: 2020-03-10 Impact factor: 6.939